Royalty Pharma plc (FRA:RPD)

Market Cap	13.62B
Revenue (ttm)	2.09B
Net Income (ttm)	1.01B
Shares Out	n/a
EPS (ttm)	2.27
PE Ratio	13.48
Forward PE	6.02
Dividend	0.80 (2.51%)
Ex-Dividend Date	May 16, 2025

Volume	n/a
Average Volume	5
Open	31.75
Previous Close	31.26
Day's Range	31.75 - 31.75
52-Week Range	23.61 - 32.04
Beta	n/a
RSI	83.99
Earnings Date	Aug 6, 2025

About Avangrid

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Country: United Kingdom
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RPD

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.